Fig. 3From: Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addictionComparison of the potency of NicA2A107R to wt NicA2 in lowering blood and brain nicotine levels in vivo. Effect of wt NicA2 or NicA2A107R treatment (0.625 mg/kg dosed i.v.) on (a) blood and (b) brain nicotine levels 3 min after 0.03 mg/kg nicotine (i.v; N = 8 rats per group). Percent remaining compared to controls are noted above each column. Control group was dosed with BSA. Mean nicotine levels ±SD. Differences between wt NicA2 and NicA2107R were significant: **** p < 0.0001, * p < 0.05. Dashed line is LOQ: 2 ng/mL for blood, 2 ng/g for brainBack to article page